PRIVATE FUNDING

  • Versant Ventures
    Versant Ventures is a leading venture capital firm specializing in investments in gamechanging biopharmaceutical and medical device opportunities. Versant pioneered the build-to-buy structured exit model, creating new companies based on insights and knowledge from the pharmaceutical and biotechnology industries. Founded in 1999, the firm consists of an experienced team of investors committed to helping entrepreneurs build successful companies that are developing breakthrough therapies for debilitating diseases. Versant has offices in the US, Canada and Switzerland.
  • La Caixa Capital Risc
    Caixa Capital Risc is the venture capital division of CaixaBank, the leading financial group in retail banking in Spain. Caixa Capital Risc manages six investment funds; Caixa Capital Micro, Caixa Capital Micro II, Caixa Capital BioMed, Caixa Innvierte BioMed II, Caixa Innvierte Industria and Caixa Capital TIC, with a total capital commitment of € 113M. Caixa Capital Risc invests in innovative Spanish companies with high growth potential, supporting them across the different stages of development. Caixa Capital Risc has invested in over 60 projects in technology-based companies in the field of life sciences, Internet, sustainability and information technology (ICT).
  • Business Angels
    Mosaic Biomedicals has four Spanish "Business Angels" including "Family Offices" and Spanish investors with experience in start-up companies and the pharmaceutical industry. These Business Angels, thanks to their experience and track-record provide us with their knowledge and contacts.

PUBLIC FUNDS

  • Ministerio de Economía y Competitividad (MINECO)
    Mosaic Biomedicals has been granted funding from the Retos de Colaboración instrument.
    El Ministerio de Economía y Competitividad español (MINECO), dentro del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, concedió ayuda al proyecto "MSC-1, un fármaco innovador y personalizado para el tratamiento del cáncer con un doble mecanismo de acción: ataca las células madre tumorales y reactiva el sistema inmune del tumor" liderado por Mosaic Biomedical con número de expediente RTC-2014-1477-1. Este proyecto ha sido financiado por el Ministerio de Economía y Competitividad (MINECO) dentro del Subprograma RETOS-COLABORACIÓN, Convocatoria 2014. El Ministerio de Economía y Competitividad español (MINECO), dentro del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016, concedió ayuda al proyecto " Desarrollo de un fármaco innovador y personalizado para el tratamiento del cáncer que reactiva el sistema inmune contra el tumor y elimina las células madre tumorales" liderado por Mosaic Biomedical con número de expediente RTC-2015-3771-1. Este proyecto ha sido financiado por el Ministerio de Economía y Competitividad (MINECO) dentro del Subprograma RETOS-COLABORACIÓN, Convocatoria 2015. El proyecto está cofinanciado por la Unión Europea con el objetivo de promover el desarrollo tecnológico, la innovación y una investigación de calidad.
  • Empresa Nacional de Innovación SA (ENISA)
    ENISA is a public company depending on the Ministry of Industry, Energy and Trurism that actively participates in the funding of viable and innovative entrepreneurial projects through the "Dirección General de Industria y de la Pequeña y Mediana Empresa".

COLLABORATIONS

  • Celgene
    Celgene seeks to deliver truly innovative and life-changing drugs for patients. Their vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
  • Vall d’Hebron Institut d’Oncologia (VHIO)
    VHIO is a leading comprehensive cancer center of excellence where its scientists and physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer.